We are live on ! Find out more
INDV icon

Indivior Pharmaceuticals
INDV

259 hedge funds and large institutions have $4.36B invested in Indivior Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 90 funds opening new positions, 84 increasing their positions, 67 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,820% more call options, than puts

Call options by funds: $78M | Put options by funds: $4.07M

246% more first-time investments, than exits

New positions opened: 90 | Existing positions closed: 26

63% more capital invested

Capital invested by funds: $2.68B → $4.36B (+$1.68B)

31% more funds holding

Funds holding: 198 → 259 (+61)

25% more repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 67

0% more funds holding in top 10

Funds holding in top 10: 10 → 10 (0)

Holders
259
Holders Change
+61
Holders Change %
+30.81%
% of All Funds
3.15%
Holding in Top 10
10
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.12%
New
90
Increased
84
Reduced
67
Closed
26
Calls
$78M
Puts
$4.07M
Net Calls
+$74M
Net Calls Change
+$18.1M

Top Buyers

1
BlackRock
BlackRock
New York
+$290M
2
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management
California
+$97.8M
3
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
+$70.4M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$61.3M
5
State Street
State Street
Massachusetts
+$56.3M

Top Sellers

1
OCM
Oaktree Capital Management
California
-$7.65B
2
TSC
Two Seas Capital
New York
-$165M
3
DM
Deerfield Management
New York
-$110M
4
Goldman Sachs
Goldman Sachs
New York
-$104M
5
NM
Newtyn Management
New York
-$50.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$654M +$290M +9,501,401 +109%
OCM
2
Oaktree Capital Management
California
$255M -$7.65B -250,676,754 -97%
Fuller & Thaler Asset Management
3
Fuller & Thaler Asset Management
California
$229M +$97.8M +3,201,639 +101%
MAP
4
Madison Avenue Partners
New York
$225M -$5.59M -183,083 -3%
Vanguard Group
5
Vanguard Group
Pennsylvania
$196M +$61.3M +2,008,078 +58%
TSC
6
Two Seas Capital
New York
$183M -$165M -5,394,954 -51%
State Street
7
State Street
Massachusetts
$167M +$56.3M +1,844,532 +66%
Morgan Stanley
8
Morgan Stanley
New York
$157M -$38M -1,245,479 -22%
DM
9
Deerfield Management
New York
$122M -$110M -3,593,748 -51%
Goldman Sachs
10
Goldman Sachs
New York
$114M -$104M -3,398,981 -52%
Citadel Advisors
11
Citadel Advisors
Florida
$110M +$13.5M +441,579 +17%
Acadian Asset Management
12
Acadian Asset Management
Massachusetts
$110M +$6.16M +201,653 +7%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$102M -$568K -18,607 -0.7%
DSCM
14
Divisadero Street Capital Management
Florida
$99.9M -$17.6M -577,819 -17%
MP
15
Mangrove Partners
Connecticut
$98.5M +$109K +3,575 +0.1%
NM
16
Newtyn Management
New York
$90.9M -$50.9M -1,665,462 -40%
Millennium Management
17
Millennium Management
New York
$83.9M +$839K +27,463 +1%
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
18
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$82.7M +$70.4M +2,304,545 New
DCM
19
Driehaus Capital Management
Illinois
$71.8M +$48.1M +1,575,955 +371%
Barclays
20
Barclays
United Kingdom
$67.4M -$7.52M -246,396 -12%
Point72 Asset Management
21
Point72 Asset Management
Connecticut
$65.4M -$31.8M -1,040,703 -36%
Arrowstreet Capital
22
Arrowstreet Capital
Massachusetts
$61.2M +$52.1M +1,705,900 New
Charles Schwab
23
Charles Schwab
California
$44.6M +$2.92M +95,650 +8%
GAM
24
Goldentree Asset Management
New York
$44.5M -$16.2M -530,000 -30%
SFM
25
Soros Fund Management
New York
$41.4M -$6.09M -199,413 -15%
1
2 3 4 5

INDV Hedge Fund Activity: Q4 2025 in Review

259 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Indivior Pharmaceuticals (INDV) for Q4 2025, worth a combined $4.36B — up 63% from $2.68B a quarter earlier.

Buyers outnumbered sellers: 90 funds opened new INDV positions and 26 closed out — a net gain of 64 holders — while 84 added to existing stakes and 67 trimmed.

The largest buyer was BlackRock, adding an estimated $290M. The largest seller was Oaktree Capital Management, cutting an estimated $7.65B.

  • 259 institutional investors held Indivior Pharmaceuticals (INDV) as of Q4 2025, up from 198 in Q3 2025.
  • Funds reported $4.36B of Indivior Pharmaceuticals stock for Q4 2025, up 63% quarter-over-quarter.
  • 90 funds opened new Indivior Pharmaceuticals positions in Q4 2025 and 26 closed out, a net change of +64 holders.
  • The largest Indivior Pharmaceuticals buyer in Q4 2025 was BlackRock, an estimated $290M added.
  • The largest Indivior Pharmaceuticals seller in Q4 2025 was Oaktree Capital Management, an estimated $7.65B sold.

Based on aggregated 13F filings for Q4 2025.